Overview

* Artivion ( AORT ) Q2 revenue rises 15% yr/yr, beating analyst expectations, per LSEG data

* Adjusted net income for Q2 beats consensus, reflecting strong operational performance

* Co exchanged $99.5 mln in convertible notes for common stock, improving capital structure

Outlook

* Artivion ( AORT ) raises full-year revenue guidance to $435 mln-$443 mln

* Company expects constant currency revenue growth of 12%-14% in 2025

* Artivion ( AORT ) increases adjusted EBITDA guidance to $86 mln-$91 mln

* Company anticipates adjusted EBITDA growth of 21%-28% for 2025

Result Drivers

* PRODUCT LINE GROWTH - Revenue growth driven by 24% increase in On-X and stent grafts, per CEO Pat Mackin

* CAPITAL STRUCTURE IMPROVEMENT - Exchange of $99.5 mln in convertible notes for common stock, effectively retiring debt

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $112.97 $108 mln

Revenue mln (7

Analysts

)

Q2 Beat $10.70 $65,000

Adjusted mln (6

Net Analysts

Income )

Q2 Net $1.34

Income mln

Q2 EBIT $8.38

mln

Q2 $64.73

Operatin mln

g

Expenses

Q2 $3.48

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Artivion Inc ( AORT ) is $33.00, about 2.2% above its August 6 closing price of $32.27

* The stock recently traded at 105 times the next 12-month earnings vs. a P/E of 165 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)